Baker Bros. Advisors’s Structure Therapeutics GPCR Stock Holding History

Baker Bros. Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$69M	Hold	1,432,529	–	–	0.4%	33
2025 Q4	$99.6M	Sell	1,432,529 -123,580	-8%	-$5.05M	0.58%	26
2025 Q3	$43.6M	Sell	1,556,109 -952,658	-38%	-$19M	0.31%	32
2025 Q2	$52M	Buy	2,508,767 +2,147,202	+594%	+$47.2M	0.5%	25
2025 Q1	$6.26M	Hold	361,565	–	–	0.07%	56
2024 Q4	$9.81M	Buy	361,565 +276,065	+323%	+$9.79M	0.1%	53
2024 Q3	$3.75M	Buy	+85,500	New	+$3.31M	0.04%	73

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Baker Bros. Advisors's GPCR Position: Q1 2026 in Review

Baker Bros. Advisors held its Structure Therapeutics (GPCR) position steady in Q1 2026 at 1,432,529 shares worth $69M. The position accounts for 0.4% of the portfolio, ranked #33.

Baker Bros. Advisors first reported a position in GPCR in Q3 2024 and has held it in 7 quarters since. The position peaked at $99.6M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Baker Bros. Advisors held 1,432,529 shares of Structure Therapeutics worth $69M as of Q1 2026.
Baker Bros. Advisors left its Structure Therapeutics share count unchanged in Q1 2026.
Structure Therapeutics made up 0.4% of Baker Bros. Advisors's portfolio in Q1 2026, its #33 holding.
Baker Bros. Advisors first reported a position in Structure Therapeutics in Q3 2024 and has held it in 7 quarters since.
Baker Bros. Advisors's Structure Therapeutics position peaked at $99.6M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.